SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+8.99%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$765M
AUM Growth
+$765M
(+22%)
Cap. Flow
+$104M
Cap. Flow
% of AUM
13.54%
Top 10 Holdings %
Top 10 Hldgs %
42.01%
Holding
140
New
30
Increased
44
Reduced
18
Closed
26
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$44.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
$33.5M |
| 3 |
Viatris
VTRS
|
$17.2M |
| 4 |
argenx
ARGX
|
$10.3M |
| 5 |
PTC Therapeutics
PTCT
|
$9.87M |
Top Sells
| 1 |
SHPG
Shire pic
SHPG
|
$21.4M |
| 2 |
Amgen
AMGN
|
$18.5M |
| 3 |
Biogen
BIIB
|
$14.5M |
| 4 |
Pfizer
PFE
|
$14.1M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$13.6M |
Sector Composition
| 1 | Healthcare | 85.91% |
| 2 | Technology | 5.46% |
| 3 | Industrials | 2.69% |
| 4 | Financials | 1.45% |
| 5 | Materials | 0.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merck
MRK
$210B
| $55.3M | 6.35% | 780,000 +100,000 | +15% | +$7.09M |
|
|
2
Viatris
VTRS
$12.3B
| $48.5M | 5.57% | 1,325,000 +471,000 | +55% | +$17.2M |
|
|
3
Johnson & Johnson
JNJ
$427B
| $44.9M | 5.16% | +325,000 | New | +$44.9M |
|
4
GSK
GSK
$79.9B
| $34.7M | 3.99% | 865,000 +100,000 | +13% | +$4.02M |
|
|
5
Bristol-Myers Squibb
BMY
$96B
| $33.5M | 3.85% | +540,000 | New | +$33.5M |
|
6
Gilead Sciences
GILD
$140B
| $32.4M | 3.72% | 420,000 +65,000 | +18% | +$5.02M |
|
7
Amicus Therapeutics
FOLD
$2.34B
| $21.6M | 2.48% | 1,787,994 +598,938 | +50% | +$7.24M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $19.7M | 2.26% | 141,700 -18,844 | -12% | -$2.62M |
|
9
Aldeyra Therapeutics
ALDX
$351M
| $15.8M | 1.81% | 1,142,089 +295,154 | +35% | +$4.07M |
|
10
Viking Therapeutics
VKTX
$3.04B
| $15M | 1.72% | 859,727 +77,303 | +10% | +$1.35M |
|
|
IMMU
11
DELISTED
Immunomedics Inc
IMMU
| $14.6M | 1.67% | 699,039 +392,384 | +128% | +$8.17M |
|
|
CLLS
12
Cellectis
CLLS
$258M
| $12.6M | 1.45% | 447,970 +96,096 | +27% | +$2.71M |
|
13
Sarepta Therapeutics
SRPT
$1.78B
| $12.3M | 1.41% | 76,116 -68,980 | -48% | -$11.1M |
|
|
BLUE
14
DELISTED
bluebird bio
BLUE
| $11.4M | 1.31% | 78,396 +5,913 | +8% | +$863K |
|
|
ARQL
15
DELISTED
Arqule Inc
ARQL
| $11.4M | 1.3% | 2,005,243 +507,560 | +34% | +$2.87M |
|
16
Minerva Neurosciences
NERV
$16.5M
| $10.6M | 1.21% | 842,391 +22,271 | +3% | +$280K |
|
17
Caesarstone
CSTE
$49.1M
| $10.4M | 1.2% | 561,311 +330,495 | +143% | +$6.13M |
|
|
18
argenx
ARGX
$43.6B
| $10.3M | 1.19% | +136,381 | New | +$10.3M |
|
|
19
PTC Therapeutics
PTCT
$3.92B
| $9.87M | 1.13% | +210,000 | New | +$9.87M |
|
20
Travere Therapeutics
TVTX
$1.56B
| $9.36M | 1.07% | 325,678 -27,394 | -8% | -$787K |
|
|
AUTL
21
Autolus Therapeutics
AUTL
$399M
| $8.94M | 1.03% | 296,251 +120,206 | +68% | +$3.63M |
|
22
BioMarin Pharmaceuticals
BMRN
$11.2B
| $8.53M | 0.98% | 88,000 +81,750 | +1,308% | +$7.93M |
|
|
SAGE
23
DELISTED
Sage Therapeutics
SAGE
| $8.48M | 0.97% | +60,000 | New | +$8.48M |
|
24
Microsoft
MSFT
$3.77T
| $7.97M | 0.91% | 69,656 -4,779 | -6% | -$547K |
|
25
ProQR Therapeutics
PRQR
$237M
| $7.72M | 0.89% | 398,749 -95,000 | -19% | -$1.84M |
|